- Home
- ANVS vs FBIO Comparison
ANVS vs FBIO Comparison
Compare ANVS & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- FBIO
- Stock Information
- Founded
- ANVS 2008
- FBIO 2006
- Country
- ANVS United States
- FBIO United States
- Employees
- ANVS N/A
- FBIO N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- FBIO Health Care
- Exchange
- ANVS Nasdaq
- FBIO Nasdaq
- Market Cap
- ANVS 55.5M
- FBIO 53.5M
- IPO Year
- ANVS 2020
- FBIO N/A
- Fundamental
- Price
- ANVS $2.74
- FBIO $2.12
- Analyst Decision
- ANVS Strong Buy
- FBIO Strong Buy
- Analyst Count
- ANVS 4
- FBIO 2
- Target Price
- ANVS $18.00
- FBIO $21.00
- AVG Volume (30 Days)
- ANVS 277.6K
- FBIO 204.0K
- Earning Date
- ANVS 08-12-2025
- FBIO 08-14-2025
- Dividend Yield
- ANVS N/A
- FBIO N/A
- EPS Growth
- ANVS N/A
- FBIO N/A
- EPS
- ANVS N/A
- FBIO N/A
- Revenue
- ANVS N/A
- FBIO $59,301,000.00
- Revenue This Year
- ANVS N/A
- FBIO $51.59
- Revenue Next Year
- ANVS N/A
- FBIO $44.74
- P/E Ratio
- ANVS N/A
- FBIO N/A
- Revenue Growth
- ANVS N/A
- FBIO N/A
- 52 Week Low
- ANVS $1.11
- FBIO $1.33
- 52 Week High
- ANVS $10.54
- FBIO $2.36
- Technical
- Relative Strength Index (RSI)
- ANVS 52.55
- FBIO 63.67
- Support Level
- ANVS $2.58
- FBIO $1.90
- Resistance Level
- ANVS $2.94
- FBIO $2.04
- Average True Range (ATR)
- ANVS 0.21
- FBIO 0.10
- MACD
- ANVS -0.00
- FBIO 0.02
- Stochastic Oscillator
- ANVS 64.41
- FBIO 81.40
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.